Please assess the completion status of the following clinical trial:

Trial Title: Study of the Safety, Pharmacodynamics (PD) and Efficacy of KRN23 in Children From 1 to 4 Years Old With X-linked Hypophosphatemia (XLH)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Male or female, aged ≥1 year and \<5 years~2. Diagnosis of XLH supported by ONE or more of the following~   * Confirmed phosphate regulating gene with homology to endopeptidases located on the X chromosome (PHEX) mutation in the patient or a directly related family member with appropriate X-linked inheritance~  * Serum fibroblast growth factor 23 (FGF23) level \> 30 pg/mL by Kainos assay~3. Biochemical findings associated with XLH including:~   * Serum phosphorus \< 3.0 mg/dL (0.97 mmol/L)~  * Serum creatinine within age-adjusted normal range~4. Radiographic evidence of rickets~5. Willing to provide access to prior medical records for the collection of historical growth, biochemical, and radiographic data and disease history~6. Provide written informed consent by a legally authorized representative after the nature of the study has been explained, and prior to any research-related procedures~7. Must, in the opinion of the investigator, be willing and able to complete all aspects of the study, adhere to the study visit schedule, and comply with the assessments~Exclusion Criteria:~1. Unwilling to stop treatment with oral phosphate and/or pharmacologic vitamin D metabolite or analog (e.g. calcitriol, alfacalcidol) during the screening period and for the duration of the study~2. Presence of nephrocalcinosis on renal ultrasound grade 4 based on the following scale: 0 = Normal, 1 = Faint hyperechogenic rim around the medullary pyramids, 2 = More intense echogenic rim with echoes faintly filling the entire pyramid, 3 = Uniformly intense echoes throughout the pyramid, 4 = Stone formation: solitary focus of echoes at the tip of the pyramid~3. Planned or recommended orthopedic surgery including staples, 8-plates or osteotomy, within the clinical trial period~4. Hypocalcemia or hypercalcemia, defined as serum calcium levels outside the age-adjusted normal limits~5. Presence or history of any condition that, in the view of the investigator, places the subject at high risk of poor treatment compliance or of not completing the study~6. Presence of a concurrent disease or condition that would interfere with study participation or affect safety~7. History of recurrent infection or predisposition to infection, or of known immunodeficiency~8. Use of any investigational product or investigational medical device within 30 days prior to screening, or requirement for any investigational agent prior to completion of all scheduled study assessments

- Gender: ALL
- Minimum Age: 1 Year
- Maximum Age: 4 Years
- Healthy Volunteers: f

Study Arms:
- Burosumab Q2W (Type: EXPERIMENTAL): Burosumab subcutaneous (SC) injections every 2 weeks (Q2W) for a total of 160 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).